What major benefits do you expect delegates will gain from attending the European Antibody Congress? In a recent interview in association with the European Antibody Congress, we posed this question to 4 of our top speakers, and here is what they had to say: "The major benefits delegates will gain from attending the European Antibody Congress consist of overview updates …
What are the top facts the antibody industry want to know?
Based on the agenda for the European Antibody Congress, what are you looking forward to learning/gaining from speaking at the congress and who from the speaking faculty are you most looking forward to hearing from, and why? In a recent interview in association with the European Antibody Congress, we posed this question to 4 of our top speakers, and here …
eBook: Why is antibody development so important?
Would knowing how the leaders in the field of antibodies think therapeutic development will continue over the next 5 years be of benefit to you? Would knowing what they want to discuss, and where they plan on having these discussions be useful information to your business? Whether you are looking to maintain, develop or enter the exciting field of antibody …
Why are we talking about antibody development?
Why is there a need to discuss antibody development, and why speak at the European Antibody Congress? In a recent interview in association with the European Antibody Congress, we posed this question to 4 of our top speakers, and here is what they had to say: "Antibodies work and are a multi-billion dollar industry with no growth end in sight …
Antibody development in the next 5 years
How valuable would knowing your peers views on how antibody therapeutics are going to develop over the next 5 years be to you? In a recent interview in association with the European Antibody Congress, we posed this question to 4 of our top speakers. Here is what they had to say: "Over the next 5 years antibody therapeutics will focus …
GeneTherapy: 2nd generation therapies from AMT, INSERM and ArkTherapeutics
AMT, INSERM and Ark Therapeutics shared goal of achieving an approved gene therapy has led them all to explore what are becoming known as the 2nd generation therapies, and they will be discussing these ideas at the World Gene Therapy Congress in London later this year. Prof Alain Fischer from INSERM will be delivering his recent results in his work …